ETFChannel.com
ATRS Description — Antares Pharma Inc.

Antares Pharma is a pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. Co. develops, manufactures and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. Co.'s U.S. Food and Drug Administration (FDA)-approved products include XYOSTED® (testosterone enanthate) injection; NOCDURNA® (desmopressin acetate); and Sumatriptan Injection USP. Co. is also the supplier of devices to Teva Pharmaceutical Industries, Ltd. for their Epinephrine Injection USP.

Company Name: 
Antares Pharma Inc.
Website: 
www.antarespharma.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree ATRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.33 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding ATRS | Antares Pharma Inc. | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.